Navigation Links
Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize
Date:10/1/2007

nary syndrome undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the adenosine diphosphate (ADP) receptor on the platelet surface. Anti-platelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and lead to heart attack or stroke.

For more information, please contact:

Jason Ford

Daiichi Sankyo, Inc.

(973) 359-2634

jaford@dsus.com


'/>"/>
SOURCE Daiichi Sankyo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Heart grows new cells
2. Body Grows Older As Cells Age
3. Emergency Department Strain As Ice Problems Grows
4. Indian Researcher Finds Human Urine Grows Better Fish Food
5. Depression has a worthwhile treatment
6. Reducing The Frequency Of Angina Attacks While Exercising
7. Some See A Hopeless End, While Others See An Endless Hope
8. Doctors Do Not Excise Sufficient Caution While Prescribing High-Risk Drugs
9. Driving While Using A Mobile Phone May Be Dangerous
10. Care for the elderly at home while away during the festive season
11. Children Face Risk While Swimming
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...cent research findings suggest that reflecting on ...logical responses to stress at low levels. Stress ... of a broad array of mental and physical health di...on the self suggest that self-affirming activities...
...ofessor Bruno DiGiovine and colleagues from Henry ...ople with lung cancer declined their interest to u...er rate than the white colored//. The study found ...s of lung cancer surgery and this misinformation h...
...riodontal disease is one of the main causes of too...ority of the tooth extractions (those with periodo...for those without// periodontal disease). It has n...tain groups of people exhibit increased susceptibi...
...lmon is considered a health food by many, because ..., its protein. A study compared the benefits of fa...// (mostly pacific salmon). Farmed salmon or Atla...e environmental pollutants such as mercury, PCBs, ...
Other Medicine News:Health News:Blacks decline Lung cancer surgery 2Health News:Nine Major Culprits For Tooth Loss Identified By Researchers 2Health News:Nine Major Culprits For Tooth Loss Identified By Researchers 3
(Date:10/6/2008)... Improve Patient Safety, WASHINGTON, Oct. 6 /PRNe...iology in collaboration with the American College ...tion today released consensus guidelines,outlining...rs and,gastrointestinal (GI) bleeding among patien...IDs) along with antiplatelet agents., Gastrointes...
(Date:10/6/2008)... Dosed Prior to Surgery, TAMPA, Fla., Oct. 6 /PRN... held ophthalmic-focused biopharmaceutical company...ophthalmic emulsion) 0.05% is now,commercially ava...od and,Drug Administration in June 2008, is a topi...eatment of inflammation and pain associated with o...
(Date:10/6/2008)...irstCall/ -- Genaera,Corporation (Nasdaq: GENR ) ...al trial of trodusquemine (MSI-1436), Genaera,s le...etes and obesity. MSI-1436 is a novel,inhibitor of... the function,of both the leptin and insulin pathw... the study, MSI-1436 was found to be well-tolerate...
(Date:10/6/2008)...patients achieved endoscopic,response and more tha... 10,in data from a 54-week open-label study presen...CG) Annual Scientific Meeting, ORLANDO, Fla., Oct...a,large, prospective study investigating endoscopi...gic compound. The data presented at the American,C...
Breaking Medicine Technology:Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 2Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 3Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Industry Executives Finding Value in Shift of Scientific Publications 5484 1Industry Executives Finding Value in Shift of Scientific Publications 5484 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2104 1Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2104 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2104 3Researchers expand natural killer cells in cord blood to fight leukemia 19605 1Researchers expand natural killer cells in cord blood to fight leukemia 19605 2New drug combination brings 1 2 punch against acute leukemia 19604 1New drug combination brings 1 2 punch against acute leukemia 19604 2
...13, 2007, 2007, SAN DIEGO, and SEOUL, South Korea,...euticals, Inc. and LG Life,Sciences, Ltd., present... (LB80380) retains potency against multiple mutant...stant to lamivudine,adefovir, entecavir or telbiv...nual Meeting of the European Association for the S...
...c Hepatitis B e-Antigen,(HBeAg)-Negative Patients ...Treatment, PRINCETON, N.J., April 13, 2007 /PRNews...day announced data from a cohort of,nucleoside-nai...V-027/901, n=99). These data showed that patients ...rus in the blood,after interruption of treatment w...
Other Medicine Technology:ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 2ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 3ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 4ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 5ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 6Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 2Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 3Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 4Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment 5
Bacterial/Viral Filters for Anesthesia and Respiratory Applications
Bacterial/Viral Filters for Anesthesia and Respiratory Applications
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours.
Medicine Products: